- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 30.03. | Stifel cuts Vor Biopharma stock price target on financing assumptions | 2 | Investing.com | ||
| 30.03. | Stifel senkt Kursziel für Vor Biopharma aufgrund neuer Finanzierungsannahmen | 2 | Investing.com Deutsch | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 30.03. | Vor Biopharma reports Q4 results | 2 | Seeking Alpha | ||
| 30.03. | Vor Bio doses first patient in phase 3 Sjögren's disease trial | 1 | Investing.com | ||
| 30.03. | Vor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | 166 | GlobeNewswire (Europe) | First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren's disease $75 million private placement strengthens balance sheet and supports telitacicept... ► Artikel lesen | |
| 30.03. | Vor Biopharma: Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease | 188 | GlobeNewswire (Europe) | BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the dosing of the first... ► Artikel lesen | |
| 30.03. | Vor Biopharma Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.03. | Vor Biopharma Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 29.03. | Jefferies startet Vor Biopharma mit Kaufempfehlung nach strategischer Neuausrichtung | 6 | Investing.com Deutsch | ||
| 29.03. | Jefferies initiates Vor Biopharma stock with buy rating on autoimmune pivot | 1 | Investing.com | ||
| 27.03. | Vor Bio raises $75M in private placement led by TCGX | 1 | Investing.com | ||
| 27.03. | Vor Bio announces $75M private placement | 2 | Seeking Alpha | ||
| 27.03. | Vor Biopharma: Vor Bio Announces $75 Million Private Placement with TCGX | 2 | GlobeNewswire (USA) | ||
| 27.03. | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.03. | Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 12.01. | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.01. | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.12.25 | Vor Biopharma: Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors | 4 | GlobeNewswire (USA) | ||
| 18.12.25 | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 3 4 Weiter >>
66 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 43,000 | 0,00 % | CRISPR Therapeutics-Aktie: Milliarden mit Gentherapie CASGEVY? | CRISPR Therapeutics vollzieht den Übergang von einem reinen Forschungsunternehmen zu einem kommerziellen Biotechnologieanbieter. Mit ersten nennenswerten Umsätzen und einer breiten Pipeline an innovativen... ► Artikel lesen | |
| EDITAS MEDICINE | 2,275 | -1,90 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| GERON | 1,417 | -1,87 % | Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Achieved $48 million and $184 million in RYTELO (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,031 | +7,02 % | SOL Global Investments Corp.: SOL Global Announces Resignation of Auditor, Anticipated Cease Trade Order and Postponement of Annual Meeting | Toronto, Ontario--(Newsfile Corp. - March 30, 2026) - SOL GLOBAL INVESTMENTS CORP. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB0) ("SOL Global" or the "Company") announces that further to its press release... ► Artikel lesen | |
| TRINITY BIOTECH | 0,590 | 0,00 % | Trinity Biotech plc: Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture Prostate Cancer Test | Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity Biotech's New York Reference Laboratory DUBLIN and NEW YORK... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,038 | -0,81 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | ||
| ARCTURUS THERAPEUTICS | 8,030 | +2,36 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,950 | +2,09 % | Ovid Therapeutics Inc.: Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer | NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need,... ► Artikel lesen | |
| CERVOMED | 3,260 | +0,62 % | CervoMed Inc.: CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates | Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026 Obtained alignment with FDA and global regulators for planned Phase 3 trial design... ► Artikel lesen | |
| EQUILLIUM | 1,648 | -4,07 % | Equillium, Inc.: Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| CABALETTA BIO | 2,965 | 0,00 % | H.C. Wainwright bekräftigt "Buy"-Rating für Cabaletta Bio | ||
| 4D MOLECULAR THERAPEUTICS | 9,490 | -3,75 % | 4D Molecular Therapeutics, Inc. - 8-K, Current Report | ||
| REGENCELL BIOSCIENCE | 30,700 | -0,32 % | VinFast, Alcoa, And Regencell Are Among the Top 10 Large-Cap Gainers Last Week (March 30-April 2): Are the Others in Your Portfolio? | ||
| THX PHARMA | 3,070 | +4,07 % | THERANEXUS: THX Pharma Announces the Publication of its Letter to Shareholders | Lyon, France - March 25, 2026, 6:30 pm CET - THX Pharma (Theranexus), an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces the publication of... ► Artikel lesen | |
| LONGEVERON | 1,070 | -5,31 % | Longeveron Announces 2025 Full Year Financial Results and Provides Business Update | On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric... ► Artikel lesen |
VOR BIOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,11 % bei einem Aktienkurs von 18,030 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.